Theranostic drug personalizes prostate cancer imaging and therapy

June 8, 2015

A novel radionuclide drug tackles the challenge of prostate cancer imaging and takes a turn as a cancer-killing therapy for tumors in and out of the prostate, according to research presented during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

The drug works by delivering diagnostic- or -grade radionuclides to cells that express a protein called prostate-specific membrane antigen (PSMA), found on the surface of and their metastatic counterparts throughout the body. Clinicians can diagnose or stage disease and monitor therapy with the aid of a special hybrid scanner used to perform minimally invasive (PET).

Full Story